Pages

Tuesday, July 6, 2021

Pre-market summary on your portfolio Delacrox

Latest 1 day change: AA +2.60%, AGR +0.31%, ARNC +0.28%, BKR +0.04%, BMY +0.59%, CNL n/a, CTVA -0.27%, CVX -0.13%, D +0.13%, DD +0.24%, DE -0.51%, DOW +0.02%, DUK -0.04%, FE -0.48%, HE -0.28%, HWM -0.52%, IBM -4.64%, JNJ +1.82%, K +0.08%, KO +0.41%, MBKL 0.0, MMM +0.40%, PFE +0.43%, PG +0.49%, PSX +0.93%, RTX +0.56%, T +0.41%, TE n/a, VTRS -0.27%, WNR n/a, XOM -0.14%

Add or remove stocks or check stock prices now.

STOCK SELECTION:  Fundamentals vs. Technical

Some investors put company financials under a microscope before buying a single share. Others swear by technical chart patterns. If you can hear BOTH perspectives before you make the trade… Your investing decisions get a lot easier! And at Stock Waves, that's our specialty. You won't believe the opportunities our analysts uncover – where fundamentals meet technicals.  Learn More »

Breaking News

PFE Israel sees decrease in Pfizer vaccine effectiveness against COVID-19 - Reuters

Analysis

IBM IBM: Bright Future Ahead by Thomas Richmond

XOM Exxon Mobil Will Likely Stay The Course by Long Player

T AT&T: 3 Reasons To Steer Clear Of The Stock by Samuel Smith

Related Analysis

AA Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q1 2021 Update by John Vincent

BKR, CTVA The R.I.P. Portfolio's Q2 2021 Update by WG Investment Research

BKR, CVX Direxion Daily Energy Bull 2x ETF: Drill, Baby, Drill by Jacob Kilby

XOM All-Weather Portfolio: The Good, The Bad, And The Ugly by Victor Dergunov

XOM, CVX TotalEnergies: Energy Major In A Period Of Transition by Nikolai Galozi

VTRS Dividend Income Summary: Lanny's June 2021 Summary by Dividend Diplomats

CVX, XOM Inflation Is Worse Than Expected: 3 Big Dividends To Beat It by Rida Morwa

RTX, BMY The Dividend Growth 30: Beating The Market And Offering An Above-Average Yield by Jonathan Weber

JNJ, MMM June 2021 Portfolio Update - Summer Brings New Highs by Wolf Report

Press Releases

PFE Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206 in ex-U.S. and ex-Asia Territories (PR Newswire)


Download Seeking Alpha for your Phone or Tablet
     

Why are you receiving this? You subscribed to Daily Portfolio Summary on your portfolio Delacrox at Seeking Alpha. Unsubscribe here.

To ensure you receive these emails in the future, please add account@seekingalpha.com to your address book, contacts or list of safe senders.

Sent by Seeking Alpha, 52 Vanderbilt Avenue, 13th floor, New York, NY 10017